Combinatorial chemoprevention of intestinal neoplasia

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 1024-1028

  Torrance, Christopher J ^a   Jackson, Peta E ^a,b   Montgomery, Elizabeth ^c   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a   Wissner, Allan ^d   Nunes, Maria ^d   Frost, Philip ^d   Discafani, Carolyn M ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EKI 569; EKI 785; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; SULINDAC; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FAMILIAL DISEASE; FEMALE; HISTOPATHOLOGY; INTESTINE CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

ADENOMATOUS POLYPOSIS COLI; ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; MICE; MICE, MUTANT STRAINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULINDAC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033827119     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79534     Document Type: Article

References (50)

1. Slack, J.L. The biology and treatment of acute progranulocyic leukemia. Curr.Opin.Oncol. 11, 9-13 (1999).
2. Johnson, S.C. & Gerber, J.G. Advances in HIV/AIDS therapy. Adv.Intern.Med. 45, 1-40 (2000).
3. Badtian, I. & Colebunders, R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 58, 633-661 (1999).
4. Hong, W.K. & Sporn, M.B. Recent advances in chemoprevention of cancer. Science 278, 1073-1077 (1997).
5. Hawk, E., Lubet, R. & Limburg, P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86, 2551-2563 (1999).
6. Giardiello, F.M. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol.Clin.North Am. 25, 349-362 (1996).
7. Gran, V.R. et al. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer.J.Sci.Am. 6, 13-20 (2000).
8. Osborne, M.P. Chemoprevention of breast cancer. Surg.Clin.North.Am. 79, 1207-1221 (1999).
9. Papadimitrakopoulou, V.A. et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch. Otolaryngol. Head Neck Surg. 125, 1083-1089 (1999).
10. Toma, S., Raffo, P., Isnardi, L. & Palumbo, R. Retinoids in lung cancer chemoprevention and treatment. Ann.Oncol. 10, 595-102 (1999).
11. Brenner, D.E. Multiagent chemopreventative agent combinations. J.Cell.Biochem.Suppl. 34, 121-124 (2000).
12. Kinzler, K.W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
13. Dubois, R.N. & Smalley, W.E. Cycloxygenases, NSAIDs and colorectal cancer. J.Gastroenterol. 6, 898-906 (1996).
14. Boolbol, S.K. et al. Cyclooxygenase-2 overexpression and tumour formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56, 2556-2560 (1996).
15. Beazer-Barclay, Y. et al. Sulindac suppresses tumourigenesis in the Min mouse. Carcinogenesis 17, 1757-1760 (1996).
16. Su, L.K. et al. Multiple intestinal neoplasia caused by mutation in the murine homolog of the APC gene. Science 256, 668-670 (1992).
17. Wolfe, M.M., Lichtenstein, D.R. & Singh, G. Gastrointestinal toxicityof non-steroidal anti-inflamatory drugs. NEJM. 340, 1888-1899 (1999).
18. Bjorkman, D.J. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am.J.Med. 105, 8S-10S (1998).
19. Kirschbaum, M.H. & Yarden, Y. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms. J. Cell. Biochem. Suppl. 34, 52-60 (2000).
20. Kapitanovic, S. et al. The expression of pi 85(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103-1113 (1997).
21. De Angelis, E. et al. Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families. Int.J.Oncol. 14, 437-440 (1999).
22. Maurer, C.A. et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum.Pathol. 29, 771-777 (1998).
23. Ozgul, C., Karaoz, E., Erdogan, D. & Dursun, A. Expression of epidermal growth factor receptor in normal colonic mucosa and in adenocarcinomas of the colon. Acta.Physiol. Hung. 85, 121-128 (1997)
24. Shirai, H. et al. Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. Anticancer.Res. 15,2889-2894 (1995).
25. Saeki, T. et al. Differential immunohistochemical detection of amphiregulin and cripto in human normal colonand colorectal tumours. Cancer Res. 52, 3467-3473 (1992).
26. Haeri, R., Pippin, J. & Drebin, J.A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress Her2/neu. Cancer Res. 60, 560-565 (2000).
27. Discafani, C.M. et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem.Pharmacol. 57, 917-925 (1999).
28. Karnes, W.E. Jr. et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 114, 930-939 (1998).
29. Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol.Ther. 82,241-250 (1999)
30. Normanno, N., De Luca, A., Salomon, D.S. & Ciardiello, F. Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. CancerDetect.Prev. 22, 62-67 (1998).
31. Ciardiello, F. et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin.CancerRes. 5, 909-916 (1999).
32. Ross, J.S. & Fletcher, J.A. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin.CancerBiol. 9, 125-138 (1999).
33. Lewis, G.D. et al. Differential responses of human tumor lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol.Immunother. 37, 255-266 (1993).
34. Williams, C.S., Mann, M. & DuBois, R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18, 7908-7916 (1999)
35. Kopp, E. & Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265, 956-959 (1994).
36. He, T.C., Chan, T.A., Vogelstein, B. & Kinzler, K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335-345 (1999).
37. Casamassimi, M. et al. EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells Ann.Oncol. 11, 319-325 (2000).
38. Kokoska, E.R., Smith, G.S., Wolff, A.B., Deshpande, Y. & Miller, T.A. Nonsteroidal anti-inflammatory drugs attenuate epidermal growth factor-induced proliferation independent of prostaglandin synthesis inhibition. J.Surg.Res. 84, 186-192 (1999).
39. Kinoshita, T. et al. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim.Biophys.Acta 1438, 120-130 (1999).
40. Winde, G. et al. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. CancerLett. 134, 201-207 (1998).
41. Vadlamudi, R. et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 18, 305-314 (1999).
42. Coffey, R.J. et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc.Natl.Acad.Sci. U.S.A. 94, 657-662 (1997).
43. Reddy, B.S. et al. Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis. 20, 1645-1648 (1999).
44. Li, H. et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumours, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20, 425-430 (1999).
45. Rao, C.V. et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51, 4528-4534 (1991).
46. Jacoby, R.F. et al. Chemopreventative efficacy of combined piroxicam and difluoromethlornithine treatment of APC mutant min mouse adenomas, and selective toxicity against APC mutant embryos. Cancer Res. 60, 1864-1870 (2000).
47. Carbone, P.P. et al. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. Cancer Epidemiol. Biomarkers Prev. 10, 907-912 (1998).
48. Laken, S.J. et al. Genotyping by mass spectrometric analysis of short DNA fragments. NatureBiotechnol. 16, 1352-1356 (1998).
49. Rudbeck, L. & Dissing, J. Rapid, simple alkaline extraction of human genomic DNA from whole blood, buccal epithelial cells, semen and forensic stains for PCR. Biotechniques. 25, 588-590 (1998).
50. Roy, S.N. & Horwitz, S.B. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res. 45, 3856-3863 (1995).